tivantinib
Overview
Tivantinib (ARQ 197) is an oral MET inhibitor investigated in advanced HCC. It is notable for a phase II trial that enriched for high c-MET expression by IHC as a predictive biomarker, forming the rationale for a phase III trial in MET-high HCC patients.
Evidence in the corpus
- c-MET is mutated in ~3% of HCC but activated/overexpressed in ~50% of advanced cases; high c-MET expression was used to enrich for response in a tivantinib phase II HCC trial, forming the biomarker rationale for phase III investigation PMID:24735922
- The 2014 HCC genomics review explicitly proposes high c-MET expression as the enrollment biomarker for tivantinib trials, alongside VEGFA amplification for sorafenib and RAS mutations for refametinib PMID:24735922
- Failed phase III in MET-high HCC: placebo OS in MET-high group was 9.1 months (longest ever reported in HCC); mechanism may be MET-independent; high MET expression may be negative prognostic marker; IHC assay/cut-off may have been miscalibrated PMID:24798001
Resistance mechanisms
Cancer types (linked)
- HCC — MET overexpression biomarker-selected phase II/III trials
Sources
This page was processed by entity-page-writer on 2026-05-11. - PMID:24798001
This page was processed by wiki-cli on 2026-05-11.